Chemomab Therapeutics (CMMB) News Today $1.07 -0.06 (-5.31%) Closing price 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Chemomab Reports Positive Phase 2 Data For Nebokitug In Primary Sclerosing CholangitisMarch 29, 2025 | nasdaq.comChemomab Therapeutics reports results in nebokitug Phase 2 PSC OLE trialMarch 28, 2025 | markets.businessinsider.comChemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver DiseaseMarch 27, 2025 | benzinga.comChemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver BiomarkersMarch 27, 2025 | globenewswire.comChemomab Therapeutics Updates ADS Offering Under Sales AgreementMarch 20, 2025 | tipranks.comNew Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic SclerosisMarch 6, 2025 | markets.businessinsider.comChemomab Therapeutics announces new scientific presentation on nebokitugMarch 6, 2025 | markets.businessinsider.comNew Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic SclerosisMarch 6, 2025 | globenewswire.comChemomab Therapeutics sees cash runway through 1Q26March 3, 2025 | markets.businessinsider.comChemomab Therapeutics reports Q4 EPS (1c) vs. (1c) last yearMarch 3, 2025 | markets.businessinsider.comChemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate UpdateMarch 3, 2025 | globenewswire.comChemomab Therapeutics price target raised to $7 from $4 at MaximFebruary 20, 2025 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)February 20, 2025 | markets.businessinsider.comChemomab completes End-of-Phase 2 Meeting with the FDA for CM-101February 19, 2025 | markets.businessinsider.comChemomab Therapeutics (CMMB) Receives a Buy from OppenheimerFebruary 19, 2025 | markets.businessinsider.comChemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing CholangitisFebruary 19, 2025 | globenewswire.comChemomab Therapeutics Ltd ADRFebruary 12, 2025 | morningstar.comChemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 3, 2025 | markets.businessinsider.comChemomab to Participate in Oppenheimer's Movers in Rare Disease SummitDecember 3, 2024 | globenewswire.comChemomab highlights clincial activity of CM-101 at The Liver Meeting 2024November 20, 2024 | markets.businessinsider.comChemomab Therapeutics Aligns Leadership Incentives with ShareholdersNovember 19, 2024 | markets.businessinsider.comOral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing CholangitisNovember 19, 2024 | globenewswire.comChemomab Therapeutics: Promising Clinical Progress and Strategic Regulatory Pathways Support Buy RatingNovember 15, 2024 | markets.businessinsider.comRoth MKM Sticks to Their Buy Rating for Chemomab Therapeutics (CMMB)November 15, 2024 | markets.businessinsider.comChemomab Therapeutics sees cash runway through beginning of 2026November 14, 2024 | markets.businessinsider.comChemomab’s Positive Trial Results Boost Investor ConfidenceNovember 14, 2024 | markets.businessinsider.comChemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business UpdateOctober 30, 2024 | markets.businessinsider.comChemomab Therapeutics to Present at October 2024 Investor ConferencesOctober 1, 2024 | stockhouse.comChemomab Therapeutics (CMMB) Gets a Buy from OppenheimerAugust 22, 2024 | markets.businessinsider.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024August 21, 2024 | investorplace.comChemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 21, 2024 | globenewswire.comChemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business UpdateAugust 12, 2024 | finance.yahoo.comChemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business UpdateAugust 12, 2024 | globenewswire.comChemomab Therapeutics Announces Closing of $10 Million Private PlacementJuly 30, 2024 | globenewswire.comChemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price RequirementJuly 26, 2024 | globenewswire.comChemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital RaiseJuly 25, 2024 | finance.yahoo.comChemomab falls on private placement despite mid-stage win for lead assetJuly 25, 2024 | msn.comChemomab Reports Positive Results For Phase 2 Trial Of CM-101July 25, 2024 | markets.businessinsider.comChemomab Collapses on Private PlacementJuly 25, 2024 | msn.comChemomab Therapeutics Announces $10 Million Private PlacementJuly 25, 2024 | globenewswire.comChemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing CholangitisJuly 25, 2024 | globenewswire.comChemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research ConferenceJune 6, 2024 | globenewswire.comChemomab Therapeutics to Participate in Upcoming Scientific ConferencesMay 17, 2024 | globenewswire.comMaxim Group Initiates Coverage of Chemomab Therapeutics - Depositary Receipt () (CMMB) with Buy RecommendationMay 14, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)May 10, 2024 | markets.businessinsider.comCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024May 9, 2024 | investorplace.comChemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comChemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleMay 8, 2024 | globenewswire.comChemomab Therapeutics to Present at 2024 Aegis Virtual ConferenceMay 2, 2024 | globenewswire.comChemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateApril 24, 2024 | globenewswire.com Remove Ads Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address CMMB Media Mentions By Week CMMB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMMB News Sentiment▼0.530.60▲Average Medical News Sentiment CMMB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMMB Articles This Week▼21▲CMMB Articles Average Week Remove Ads Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IKNA News Today ENTX News Today ACHL News Today PYXS News Today UNCY News Today SCLX News Today ANRO News Today QNCX News Today INZY News Today OKUR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMMB) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
